British Scientists: Producing High-quality Stem Cells
British scientists said they have produced first-class "gold standard" stem cells, which could trigger a wave of new treatments for degenerative diseases.
The stem cells from human embryos will be available to researchers for clinical trials by the end of next year, the Daily Telegraph reported Tuesday.
Previous embryonic stem cell trials in humans have used low-quality "research-grade" stem cells, which have been reprogrammed as "clinical-grade" after treatment, while new stem cells have "clinical-grade" quality when donated without costly and dangerous conversion processes, the researchers said.
Researchers at King's College, University of London, donated these stem cells to the British stem cell bank. These stem cells will be tested here to ensure that they are safe and harmless, and reach the quality that can be used in human trials.
Peter Braud, a leading member of the King's College research team, said: "As far as regenerative medicine is concerned, stem cells that can be put into clinical use at any time are the 'Holy Grail' that everyone yearns for."
According to the Daily Telegraph, these stem cells take needle-sized embryos donated by patients who are free to receive artificial insemination. They are no longer of any use to the patients themselves and will be thrown away even if they are not donated.
- June 18, 2019Researchers used stem cells from human embryos to successfully treat Parkinson's disease in mice and rats. This is a crucial step in finding similar treatments for humans. In a study published Sunday ...view
- May 16, 2019Professor shinya yamanaka, director of the institute of Induced Pluripotent Stem Cells (ips) at Kyoto university, and his team have discovered the Glis1 gene that is an important component of the Indu...view
- May 16, 2019Scientists are using stem cells to create artificial blood that will be tested in the UK in two years. The scientists that are doing the research believe it could change the way blood transfusions are...view